Table 3.
Subgroup analysis of the association between FAR and 28-day mortality.
| Subgroups | N | Adjusted HR (95% CI) | P for interaction | ||||
|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | ||||
| Age (years) | < 70 | 2,935 | 1.32 (1.06–1.64) | 1 (Ref) | 1.09 (0.86–1.38) | 0.93 (0.73–1.19) | 0.058 |
| ≥ 70 | 1,680 | 0.91 (0.67–1.23) | 1 (Ref) | 1.24 (0.96–1.59) | 1.32 (1.02–1.71) | ||
| Gender | Female | 1864 | 1.14 (0.87–1.50) | 1 (Ref) | 1.21 (0.93–1.58) | 1.17 (0.90–1.54) | 0.372 |
| Male | 2,751 | 1.18 (0.95–1.48) | 1 (Ref) | 1.14 (0.91–1.42) | 1.06 (0.84–1.34) | ||
| Diabetes mellitus | No | 3,350 | 1.15 (0.95–1.40) | 1 (Ref) | 1.11 (0.91–1.36) | 1.04 (0.85–1.27) | 0.099 |
| Yes | 1,265 | 1.29 (0.87–1.91) | 1 (Ref) | 1.41 (1.01–2.01) | 1.38 (0.96–1.99) | ||
| Severe liver disease | No | 3,928 | 1.23 (0.99–1.52) | 1 (Ref) | 1.22 (1.01–1.48) | 1.15 (0.95–1.40) | 0.158 |
| Yes | 687 | 1.01 (0.75–1.37) | 1 (Ref) | 0.91 (0.6–1.36) | 0.74 (0.39–1.38) | ||
| Malignant cancer | No | 3,973 | 1.13 (0.93–1.36) | 1 (Ref) | 1.26 (1.05–1.52) | 1.03 (0.84–1.25) | 0.661 |
| Yes | 642 | 1.46 (0.94–2.27) | 1 (Ref) | 0.82 (0.54–1.24) | 1.16 (0.78–1.74) | ||
| Metastatic solid tumor | No | 4,376 | 1.15 (0.96–1.37) | 1 (Ref) | 1.22 (1.02–1.46) | 1.06 (0.88–1.28) | 0.560 |
| Yes | 239 | 1.57 (0.77–3.19) | 1 (Ref) | 0.72 (0.39–1.32) | 1.00 (0.55–1.79) | ||
| SOFA | < 4 | 638 | 1.19 (0.54–2.62) | 1 (Ref) | 1.65 (0.87–3.15) | 1.74 (0.91–3.34) | 0.125 |
| ≥ 4 | 3,977 | 1.19 (1.00–1.42) | 1 (Ref) | 1.15 (0.97–1.38) | 1.06 (0.88–1.27) | ||
| CRRT | No | 3,862 | 1.25 (1.02–1.54) | 1 (Ref) | 1.38 (1.13–1.68) | 1.20 (0.97–1.48) | 0.018* |
| Yes | 753 | 0.95 (0.70–1.31) | 1 (Ref) | 0.71 (0.50–1.01) | 0.78 (0.55–1.11) | ||
FAR, fibrinogen to albumin ratio; HR, hazard ratio; CI, confidence interval; SOFA, sequential organ failure assessment; CRRT, continuous renal replacement therapy.